Skip to main content
. 2016 Mar 8;25(10):1979–1989. doi: 10.1093/hmg/ddw073

Figure 6.

Figure 6.

ASC-JM17 ameliorates the disease phenotype in AR97Q mice and reduces mutant AR accumulation in vivo. (A) Picture of two representative AR97Q mice from the same litter treated with 120 mg/kg of ASC-JM17 or vehicle for 6 weeks. (B and C) Body weight (B) and hang time (C) of AR97Q mice treated with ASC-JM17 or vehicle daily from 10 to 26 weeks of age (n = 15 per group). Data are expressed as mean ± SEM (two-way ANOVA). (D) Representative cross-sections of quadriceps muscle from AR97Q mice following treatment with vehicle or ASC-JM17 for 6 weeks. Sections were processed with H&E or NADH staining. Scale bar: 50 μm. (E) AR protein levels in quadriceps muscle of AR97Q mice. (F) Quantification of the monomeric and high molecular weight (HMW) AR signal shown in (E) (n = 3). Data are expressed as mean ± SEM. *P < 0.05 (Student's t-test). (G) Quantification of 1C2-positive nuclei in quadriceps muscle of AR97Q mice (n = 3 per group). Data are expressed as mean ± SEM. **P < 0.01 (Student's t-test).